Medications
Research team develops novel PTPN2/N1 inhibitor for cancer immunotherapy using generative AI
In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. But while immunotherapy drugs offer new treatment possibilities, only about 20% to 40% of patients respond ...
Apr 11, 2024
0
1
